Extended Data Fig. 6: SCG2 loss restricts tumor progression in LILRB4-Tg mice.
From: Secretogranin 2 binds LILRB4 resulting in immunosuppression
a, Immunoblot analysis of SCG2 expression levels in brain tissues and serum from LILRB4-Tg and LILRB4-Tg SCG2−/- mice (n = 5). b, Percentages of immune cell populations in spleens from WT, SCG2−/-, LILRB4-Tg, and LILRB4-Tg SCG2−/-, mice (n = 6). c, Representative images of excised tumors (MC38, EO771, LLC, and CT2A models) from indicated mouse groups at study endpoint. d-e, Tumor growth curves and final tumor weights showing no significant difference between SCG2−/- mice and WT mice bearing MC38 (n = 6) or LLC (n = 6) tumors. Tumor volumes were measured every two days; tumors were excised and weighed at endpoint. f, MC38 tumor growth in WT, LILRB4-Tg, mice and LILRB4-Tg SCG2−/- mice. Tumor size was measured every two days, and tumor weights were measured on the final day (n = 9 or 10). g, Tumor growth in WT or ApoE−/- mice. Mice were subcutaneously implanted with LLC cells (5×105) on the right flank. Tumor size was measured every two days, and tumor weights were measured on the final day (n = 7 or 8). h, Representative immunofluorescence staining and quantification of CD8+ T cells and M-MDSCs in MC38 tumors from LILRB4-Tg mice and LILRB4-Tg SCG2−/- mice (3 independent experiments, n = 10). Scale bars, 100 µm. i, Quantification of immune cell infiltration (M-MDSCs, G-MDSCs, macrophages, cDC1, cDC2, CD4+ and CD8+ T cells) in tumor tissues (B16F10 (n = 8), LLC (n = 9), EO771 (n = 8) and CT2A (n = 8)) isolated from LILRB4-Tg mice and LILRB4-Tg SCG2−/- mice at endpoint. Tumor growth data are present as mean ± s.e.m.; all other data are present as mean ± s.d. p values were determined by two-tailed unpaired Student’s t-test or two-way ANOVA with Bonferroni’s multiple comparisons test (tumor volume (d-g)).
